# persona_off · bixbench · bix-10-q3

[All trial-1 traces](../../README.md)

- Trial: **1**; endpoint: **original**; attempt: **1**.
- Native status: **scored**; normalized native score: **0/100**.
- Recorded protocol: `researcher-review-v2`.
- Actor, simulator, and judge: **GPT-6 Astra, low reasoning**.
- Scope: chronological shared messages and handoff fields. Private tool logs, system prompts, evaluator references, and raw API requests are not included.
- A repaired endpoint belongs to the same trial; it is not an independent repeat. Zero scores and missing scientific submissions are retained.

## Shared conversation

### Event 1 — Simulator

**Message**

````text
Inspect the supplied files and any repository documentation only; do not run the main hypothesis tests yet. Report dataset shapes, subject identifiers and duplication, treatment labels and their mapping to BCG/placebo, patients_seen values and missingness, and how COVID-19 events and severity are represented. Check whether CSV/XLSX files are equivalent alternatives and whether repeated COVID-19 events occur per subject. Propose a chi-square analysis comparing treatment and COVID-19 severity within each recorded patient-volume group, explaining inclusion criteria, join strategy, unit of analysis, handling of repeated events/missing data, and test settings. Identify consequential coding ambiguities or assumptions rather than inferring undocumented meanings. Include the planned reproducible script/notebook location; execution and the final answer will follow approach review.
````

**Interaction**

````text
initial_request
````

**Phase**

````text
initial_inspection
````

**Action**

````text
continue
````

**Approve Approach**

````text
false
````

**Evidence**

````text
Available schema identifies patients_seen in DM, treatment and subject identifiers across tables, and event terminology and AESEV in AE; actual values, coding meanings, and suitable analysis population have not yet been inspected.
````

**Objectives Open**

````text
[
  "Inspect data and documentation to establish patient-volume groups, treatment mapping, and COVID-19 severity definition.",
  "Agree on analysis population, repeated-event handling, and chi-square approach before executing tests.",
  "Execute approved analysis and provide a concise answer with a retained analysis artifact."
]
````

### Event 12 — Actor

**Answer**

````text
Inspection only is complete; no hypothesis tests have been run. Please approve or revise the proposed choices below before implementation.

INPUT AUDIT
• Only the six supplied data files and task.json are present; no data dictionary, protocol, or repository documentation explains the codes.
• DM: 1,000 rows × 11 columns; EX: 4,998 × 12; AE: 2,694 × 51. Each contains the same 1,000 nonmissing USUBJID identifiers (lexical range BCG0001–BCG5500). DM has one row per subject. EX has 998 subjects with five rows and two with four; these are administration-question records, not independent vaccinations. AE has 1,694 rows beyond one per subject. No table has exact duplicate rows. Among AE records with AESPID present, 105 repeat the (USUBJID, AESPID) key, so this is not a unique event identifier.
• TRTGRP explicitly contains BCG and Placebo, 500 subjects each. Labels agree across all tables. EX confirms BCG maps to “Bacillus Calmette-Guérin (vaccine)” and Placebo to “0.9% NaCl,” each for 500 subjects. Do not infer treatment from the BCG prefix in subject identifiers.
• patients_seen is a complete DM categorical field: 1-50 = 835 subjects, 51-100 = 129, >100 = 36. No time unit is documented. All DM and EX fields are nonmissing.
• COVID is represented through AE preferred terms, not a separate subject-level COVID status variable: AEPT='COVID-19' has 207 records; 'COVID-19 pneumonia' has 9; 'Asymptomatic COVID-19' has 5; 'SARS-CoV-2 test positive' has 3. COVID-19 itself is mostly categorized RTI, but one record is Other, so AECAT='RTI' should not be required.
• AESEV has numeric codes 1, 2, 3, 4, with no documented clinical labels. Overall counts are 1:1,238, 2:741, 3:64, 4:20, missing:631. Separate AEHS, AEHSFU, OnsetHS, and weekly HS fields exist; these must not silently be substituted for AESEV. AE contains 143 rows missing event descriptors/AESPID; absence of an event cannot be assigned severity zero.
• Exact COVID-19 records cover 189 subjects: 176 have one record, eight two, five three. AESEV counts are 1:55, 2:89, 3:13, 4:6, missing:44. Adding pneumonia and asymptomatic COVID gives 221 records in 194 subjects (177 with one, seven with two, ten with three), with severity counts 1:57, 2:91, 3:19, 4:7, missing:47. Adding positive SARS-CoV-2 tests gives 224 records in 197 subjects, 48 missing severity. Repeated records include identical AESPID with differing dates/severities: BCG0145 has code 1 at day 174 and code 4 at day 178, both AESPID=1. Others have different AESPID and widely separated dates. These cannot all be assumed to be independent infections or simple duplicate rows.
• CSV/XLSX have matching shapes, columns, row ordering, and analysis-variable values. EX matches; AE matches after normalizing numeric-versus-string storage in mixed columns (OnsetHS, AEWK1HS, AEWK2HS and one AESOC cell). DM differs in six Age cells: CSV '10-19' becomes Excel date 2025-10-19. Thus they are alternative representations for this analysis, not extra observations, but not literally identical files. Prefer CSV; EX needs cp1252 decoding for the vaccine name.

PROPOSED ANALYSIS
1. Use CSV inputs; take subject treatment and recorded volume group from DM. Validate nonmissing unique DM identifiers and treatment consistency. Filter AE to the three explicit COVID disease terms (COVID-19, COVID-19 pneumonia, Asymptomatic COVID-19), without an RTI restriction. Exclude the three test-positive-only records in the primary analysis, and examine their inclusion as a sensitivity analysis. Also show exact-term-only results to expose the consequential difference from a literal AEPT='COVID-19' filter.
2. Join filtered AE to DM on USUBJID with many-to-one validation and an unmatched-ID audit. Do not join raw EX, which would multiply observations; use it only to validate treatment mapping.
3. Primary unit: one healthcare worker, not one AE record. Propose maximum observed AESEV across qualifying records per subject, explicitly conditional on approval of the assumption that higher numeric codes indicate greater severity. This is a transparent maximum-recorded-severity endpoint, not a documented protocol endpoint. Keep numeric categories without assigning clinical names. Exclude subjects with all qualifying severity values missing; retain subjects with at least one recorded value, flagging their partially missing histories. Do not impute missing severity or code noncases as severity zero. Report exclusions by treatment and volume. As sensitivity checks, compare earliest recorded qualifying severity and the naive event-row tables; the latter are descriptive/sensitivity only because repeated subjects violate independence.
4. For each of the three recorded patients_seen groups, construct treatment × categorical AESEV counts. Run Pearson chi-square via scipy.stats.chi2_contingency(..., correction=False, lambda_=None). Remove only all-zero severity columns, never pool categories post hoc; report nonestimable tables if fewer than two populated rows/columns. Use nominal p<0.05, with no multiplicity adjustment because none is requested; explicitly identify the three tests as unadjusted. Record chi-square, degrees of freedom, p-value, expected counts, minimum expected count, and proportion below five. Sparse strata may make the asymptotic p-values unreliable; report this rather than silently replacing the required test.
5. Planned reproducible artifact: analysis/covid_severity_chisquare.py, with audit tables and test outputs saved under analysis/outputs/. It has not yet been created or executed. After approval, execute it and provide the concise answer supported by full tables, diagnostics, and sensitivity results.

The choices requiring review are the COVID term inclusion rule and subject-level severity summary. Treating all AE rows as independent or treating undocumented severity codes as named clinical grades would materially change interpretation.
````

**Stage**

````text
plan
````

**Evidence**

````text
Observed shapes: DM 1000×11, EX 4998×12, AE 2694×51. All tables share 1000 IDs and have zero treatment mismatches against DM and zero full-row duplicates. Volume counts: 835/129/36. Exact COVID: 207 records, 189 subjects, 44 missing AESEV; three disease terms: 221 records, 194 subjects, 47 missing AESEV. Repeated COVID records and conflicting severity within identical subject/event keys were directly inspected. No chi-square tests or p-values were calculated.
````

**Assumptions**

````text
[
  "AESEV is the intended severity field, inferred from its name rather than a supplied dictionary.",
  "Maximum numeric AESEV is an appropriate subject-level summary only if larger codes mean more severe disease; this requires explicit approach approval.",
  "Primary inference concerns severity among subjects with recorded COVID disease and available severity, not infection risk among all randomized subjects."
]
````

**Uncertainties**

````text
[
  "No documented severity code meanings or patients_seen time unit are supplied.",
  "Repeated AE records may be updates, related complications, or separate episodes; AESPID does not uniquely identify a row.",
  "Exact COVID term versus broader disease terms versus positive-test inclusion is not specified in the question.",
  "Sparse volume strata and severity missingness may limit chi-square validity and generalizability."
]
````

### Event 13 — Simulator

**Message**

````text
Proceed with the proposed analysis and execute analysis/covid_severity_chisquare.py. Approve the three explicit COVID disease terms and one-subject maximum-observed-AESEV primary endpoint as analytical assumptions, not confirmed source intent. The ordinal interpretation of numeric AESEV remains undocumented; retain numeric labels and state this limitation. Your proposed exact-COVID-only, positive-test-inclusive, earliest-recorded-severity, and event-row sensitivity analyses will help establish whether the answer depends on these choices. For earliest recorded severity, specify date parsing and ties without assuming undocumented event chronology. Keep event-row tests explicitly non-independent sensitivity results, not primary inference. Use the recorded patient-volume groups, unadjusted Pearson chi-square with correction=False, and the proposed missing-data and join safeguards. Report contingency tables, analyzed subject counts and exclusions, p-values and expected-count diagnostics for all three strata, along with a compact comparison of sensitivity results. If the significant group changes across reasonable definitions, make that uncertainty explicit rather than selecting a definition based on significance. Deliver a concise answer naming the significant patient-volume group(s), or none if applicable, with p-values and any material sparse-table caveat. Include the final submission fields stage, answer, payload.executed_analysis, and artifacts.analysis pointing to the executed script.
````

**Interaction**

````text
next_task
````

**Phase**

````text
approach_review
````

**Action**

````text
continue
````

**Approve Approach**

````text
true
````

**Evidence**

````text
Inspection reports explicit treatment labels, three complete patient-volume categories, agreement of analysis variables across file formats, and repeated COVID AE records that justify avoiding independent-event primary inference. No codebook resolves severity ordering or disease-term scope, so the proposed choices require transparent assumptions and sensitivity reporting. No tests have yet been executed.
````

**Objectives Open**

````text
[
  "Execute reproducible stratified chi-square analysis and inspect contingency tables and expected-count diagnostics.",
  "Determine which patient-volume groups satisfy nominal p<0.05 and whether the conclusion is sensitive to endpoint definitions.",
  "Provide a concise final answer and executed analysis artifact under the submission contract."
]
````

### Event 16 — Actor

**Answer**

````text
No patient-volume group was significant under the approved primary analysis (one subject’s maximum observed numeric AESEV): 1–50 patients, p=0.2636; 51–100, p=0.3748; >100, p=0.4033. However, using earliest recorded nonmissing severity instead makes the 1–50 group significant (p=0.0303). Thus the answer depends on the severity-summary definition. All primary tables have sparse expected counts, especially >100, so asymptotic chi-square results warrant caution; severity-code ordering is undocumented.
````

**Stage**

````text
result
````

**Evidence**

````text
Executed `python analysis/covid_severity_chisquare.py` successfully (exit code 0). All joins passed many-to-one validation and all AE/EX treatment labels matched DM. Pearson chi-square used correction=False, no multiplicity adjustment, numeric severity categories, and only removal of all-zero columns.

PRIMARY CONTINGENCY TABLES (columns AESEV 1,2,3,4):
1–50: BCG [24,26,8,3], Placebo [16,28,2,2]; N=109 (61 BCG,48 placebo), chi2=3.980232, df=3, p=0.263607; minimum expected=2.201835; 3/8 expected cells <5.
51–100: BCG [5,6,0,1], Placebo [8,13,0,0]; N=33 (12,21), chi2=1.962695, df=2 after dropping all-zero code 3; p=0.374806; minimum expected=0.363636; 3/6 cells <5.
>100: BCG [0,3,0,1], Placebo [1,3,1,0]; N=9 (4,5), chi2=2.925000, df=3, p=0.403334; minimum expected=0.444444; 8/8 cells <5.

INCLUSION/EXCLUSIONS:
Primary disease definition: COVID-19, COVID-19 pneumonia, Asymptomatic COVID-19. 221 records in 194 subjects; 47 records missing AESEV. Excluded 43 subjects with entirely missing qualifying severity; retained 151 subjects, including four with partially missing severity histories. Of 1,000 DM subjects, 806 lacked a qualifying disease record and were outside this conditional-severity analysis, not assigned severity zero.
By group, qualifying subjects → analyzed (all-missing excluded):
1–50: BCG 80→61 (19), placebo 67→48 (19); qualifying missing-severity records 20 and 20. Two retained subjects have partial missingness.
51–100: BCG 15→12 (3), placebo 22→21 (1); missing-severity records 4 and 1. One retained subject has partial missingness.
>100: BCG 5→4 (1), placebo 5→5 (0); missing-severity records 2 and 0. One retained subject has partial missingness.

SENSITIVITY COMPARISON (p-values in group order 1–50 / 51–100 / >100):
Primary maximum: .263607 / .374806 / .403334; N=109/33/9.
Exact COVID-19 term, subject maximum: .072720 / .374806 / .403334; N=106/33/9.
Positive-test-inclusive, subject maximum: .298492 / .374806 / .403334; N=111/33/9.
Earliest recorded nonmissing severity: .030317 / .374806 / .342782; N=109/33/9.
Event rows, explicitly non-independent: .073495 / .309587 / .414179; 128/34/12 records representing 109/33/9 subjects.

Earliest rule: parsed AESTDTC with pandas.to_numeric, validating that no nonmissing value failed parsing. No calendar origin or clinical chronology was inferred. Among records with nonmissing severity and numeric AESTDTC, selected the smallest recorded numeric date per subject; tied minima summarized by maximum numeric severity. No qualifying date values were missing. This endpoint is earliest OBSERVED severity, not necessarily first infection severity. For its significant 1–50 table, minimum expected count=0.440367 and 4/8 expected counts <5, further weakening asymptotic reliability.

All primary and sensitivity observed and expected tables are saved individually under analysis/outputs/; test_results.csv includes each test’s sample size, chi-square, df, p-value and expected-count diagnostics. inclusion_audit.csv includes treatment-specific exclusions for every definition.
````

**Assumptions**

````text
[
  "Three explicit COVID disease terms and maximum numeric AESEV per subject were approved analytical choices, not confirmed source intent.",
  "Higher AESEV codes were treated as more severe solely for the maximum endpoint and earliest-date tie rule; numeric labels were retained.",
  "Nominal unadjusted p<0.05 defines significance across the three recorded patient-volume strata."
]
````

**Uncertainties**

````text
[
  "The significant group changes with the repeated-record summary: none for primary maximum versus 1–50 for earliest observed severity. No unique definition-independent answer is supported.",
  "Numeric AESEV ordering and clinical category meanings are undocumented.",
  "Repeated event records cannot reliably be classified as updates versus distinct episodes. Event-row p-values do not provide independent-subject inference.",
  "Sparse expected counts affect every primary stratum; the >100 stratum has only nine analyzed subjects. Missing severity may introduce selection bias."
]
````

### Event 17 — Simulator

**Message**

````text
The reported execution adequately addresses the approved analysis and its consequential ambiguities. Finalize with stage='final', retain payload.executed_analysis=true and artifacts.analysis='analysis/covid_severity_chisquare.py'. Use a concise answer: 'No patient-volume group showed a significant difference under the subject-level maximum-severity analysis (1–50: p=0.2636; 51–100: p=0.3748; >100: p=0.4033). The 1–50 group was significant only in the earliest-recorded-severity sensitivity analysis (p=0.0303). The conclusion therefore depends on the severity summary, and sparse expected counts limit chi-square reliability.' Do not present the sensitivity finding as an unqualified primary conclusion.
````

**Interaction**

````text
conclude
````

**Phase**

````text
result_review
````

**Action**

````text
stop
````

**Approve Approach**

````text
false
````

**Evidence**

````text
The agent reports successful script execution, validated joins, primary contingency tables and exclusion counts, all requested sensitivity comparisons, and expected-count diagnostics. No primary p-value is below 0.05; earliest recorded severity yields p=0.030317 for 1–50 only. The analysis artifact is supplied. These reported results satisfy the agreed approach without resolving undocumented severity ordering or source intent, which are appropriately disclosed as limitations.
````

**Objectives Open**

````text
[]
````

## Provenance

````text
{
  "source_run": "runs/openai-astra-top2-first-pass",
  "repair_run": "runs/repair-1-openai-astra-top2-first-pass",
  "event_log": "runs/openai-astra-top2-first-pass/episodes/bixbench_bix-10-q3-22819615c3e3/persona_off/attempt-1/output/bixbench_bix-10-q3-22819615c3e3/controller/events.jsonl",
  "event_log_sha256": "2d25d56d45bc9bd4da3cf54c0a6e6d0273787508c12b8d10dac96a72b2182c0a",
  "models": {
    "actor": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "researcher": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "judge": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    }
  }
}
````
